The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

doi:10.1093/neuonc/noae259

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

Neuro-oncology - 21 Jun 2025

de la Fuente Macarena I, Touat Mehdi, van den Bent Martin J, Preusser Matthias, Peters Katherine B, Young Robert J, Huang Raymond Y, Ellingson Benjamin M, Capper David, Phillips Joanna J, Halasz Lia M, Shih Helen A, Rudà Roberta, Lim-Fat Mary Jane, Blumenthal Deborah T, Weller Michael, Arakawa Yoshiki, Whittle James R, Ducray François, Reardon David A, Bi Wenya Linda, Minniti Giuseppe, Rahman Rifaquat, Hervey-Jumper Shawn, Chang Susan M, Wen Patrick Y

Abstract excerpt

Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to IDH1 gene

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Pyrimidines

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 39723472
DOI: 10.1093/neuonc/noae259
PMCID: PMC12187374

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.PMID 39723472Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.Semantic proximity Read ↗

Vorasidenib: First Approval.Semantic proximity Read ↗

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.Semantic proximity Read ↗

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.Semantic proximity Read ↗

Current and promising treatment strategies in glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.